Pioneering a new approach to biological discovery

IPI blends academic exploration with industrial scalability
to tap the full potential of recombinant antibodies.

About usContact us

Our proteins power discovery

IPI is a nonprofit research hybrid that invests in high-throughput technologies and deep protein expertise to bring biological research up to speed.

About IPI →

Woman in glasses and lab coat holding pipette.

Academic expertise

Our Harvard-based scientists collaboratively take on complex projects in the areas most in need of transformative antibodies and other proteins.

Learn about our research →

Man working in cell biology lab.

Industrial platform

We achieve unprecedented scale with a platform and technologies based on high-quality protein and antibody design, expression and production.

Learn about our Platform →

IPI in brief

Drawing Of Microscope.

Meeting research needs

IPI scientists deploy cutting-edge technologies and techniques, such as antibody engineering and a yeast display library, to tap the full potential of synthetic recombinant antibodies.

Basic Drawing Of Antibody.

Best of both worlds

IPI combines deep academic expertise with industrial scalability, investing in high-throughput technologies and automation to bring biological research up to speed.

Figure Representing Business Model.

Unique business model

IPI is a nonprofit institute with assured funding and the high-caliber expertise to support exploratory protein research.

Drawing Of Lightbulb.

Cross-disciplinary connections

IPI is poised to elevate life science communities, collaborating with biologists across specialties and training young scientists.

Building collaborations

IPI believes the best science crosses fields. We draw together multiple disciplines to build antigen and antibody tools for basic biological research and therapeutic discovery.

Collaborate with us →

News from the lab

More IPI news →

Screenshot of video showing integrin mechanotransduction.

Human foreskin fibroblasts were seeded on a surface presenting LDVP-TGTs (<33 pN). Dorsal and ventral surfaces of spreading cells were monitored via differential interference contrast (DIC) microscopy and reflection interference contrast microscopy (RICM). Clustering of integrin α4 (fluorescently labeled antigen-binding fragment) and force transmission through integrin α4β1 (fluorescent probe-quencher pair) were monitored using total internal reflection fluorescence microscopy. Image courtesy of Myung Hyun Jo.
Science news

Uncovering the secrets of mechanotransduction, one integrin receptor at a time

For the body to function, cells must decide. Embryonic cells elect to reproduce and shape into budding limbs. Immune cells choose to leave the bloodstream en...

Read more
Scientist viewing robot in lab.

Scientist Roushu Zhang performs protein purification. IPI photo by Caitlin Faulds.
Core concepts

Engineering Protein A to Z for VH3 antibody purification

Antibody purification is often taken for granted. It’s an essential step in isolating desirable antibodies for research and drug development and a standard part of antibody...

Read more
Hand holding pipette and tube.

Hand holding pipette and tube. IPI photo by Pat Piasecki.
Core concepts

Inside the IPI pipeline

Of the tools underpinning biomedical research, antibodies are among the most impactful. Their ability to recognize and attach to biomolecules has powered fundamental discoveries, diagnostic methods...

Read more
Bioscience leader Ken Fasman to steer IPI as new president and CEO

Kenneth Fasman in the IPI lab. IPI photo by Caitlin Faulds.
People

Bioscience leader Ken Fasman to steer IPI as new president and CEO

The walls of Ken Fasman’s ninth-floor office are still bare. But the new president and CEO at the Institute for Protein Innovation (IPI) has plans that...

Read more
LinkedInTwitterInstagram

Get in touch today

Contact us
Back To Top